Addressing the Challenges in HCC Treatment with Innovative Technology
Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.
Hepatocellular carcinoma (HCC) poses a significant global health challenge, being a predominant form of liver cancer with high mortality rates. The disease exhibits sexual dimorphism, disproportionately affecting males.
Despite the crucial role of androgen receptors (AR) in HCC progression, anti-androgen therapies have shown limited efficacy. Recent discoveries of ligand-independent AR splice variants (AR-SVs) in HCC have opened new avenues for therapeutic intervention. However, the potential of niclosamide, a promising anti-HCC agent, has been hindered by poor bioavailability and dose-limiting toxicities.
Researchers at The Ohio State University have developed novel analogues of niclosamide, a proven anthelmintic drug, to enhance its therapeutic potential against AR/AR-SV positive HCC. By leveraging the insights gained from key functional groups of niclosamide, our approach aims to improve bioavailability, reduce first-pass metabolism, and mitigate dose-limiting toxicities.
Provisional Patent Application pending